Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
The U.S. Department of Agriculture is urging poultry producers to intensify bird flu testing. The WHO is advocating for U.S.
We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
European stocks advanced for four consecutive weeks as miners rose on a report Rio Tinto Group and Glencore Plc have ...
The health sector is witnessing crucial developments including US turkey flu testing advocacy, WHO lobbying to retain US membership, and Medicare price negotiations involving major drugs. Meanwhile, ...
President-elect Donald Trump says he “most likely” will give TikTok 90 more days to work out a deal that would allow the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback